[Lymphocyte subpopulations in non-Hodgkin's lymphoma during cytostatic therapy].
1. In non-Hodgkin-lymphomas with leucaemic form of the course a significant percental decrease of the number of T-lymphocytes and an also significant increase of the number of B-lymphocytes was to be proved. The increase of the B-lymphocytes concerned among others cells which carry the ME-receptor. 2. In non-Hodgkin-lymphomas with aleucaemic form of the course in decrease of the absolute number of lymphocytes a relative and absolute increase of the subpopulation of lymphocytes carrying the ME-receptor was provable. 3. In the course control of 7 patients with non-Hodgkin-lymphoma under polychemotherapy in 5 cases a discrepancy between the number of rosette-forming cells and the total number of lymphocytes appeared. 4. In the monotherapy of patients with CLL in favourable clinical development a percental increase of the T-cells is objectifiable after one year. A similar development was to be found in 3 patients after the first cycle with CVP.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000187:drug effects*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007958:Leukocyte Count; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011961:Receptors, Fc / Q000276:immunology; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000187:drug effects*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011961:Receptors, Fc; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone
Untersuchungen von Lymphozytensubpopulationen bei Non-Hodgkin-Lymphomen im Verlaufe der Zytostatikatherapie.